Clofibrate

• Description :

  Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ～500 μM for murine PPARα and PPARγ, and 55 μM, ～500 μM for human PPARα and PPARγ, respectively.

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H318, H335

• Target :

  PPAR

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/Clofibrate.html

• Purity :

  99.61

• Solubility :

  DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL

• Smiles :

  CC(C)(OC1=CC=C(Cl)C=C1)C(OCC)=O

• Molecular Formula :

  C12H15ClO3

• Molecular Weight :

  242.70

• Precautions :

  H302, H315, H318, H335

• References & Citations :

  [1]Willson TM, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000 Feb 24;43 (4) :527-50.|[2]Chen Y, et al. Clofibrate Attenuates ROS Production by Lipid Overload in Cultured Rat Hepatoma Cells. J Pharm Pharm Sci. 2017;20 (0) :239-251.|[3]Chen SH, et al. Prenatal PPARα activation by clofibrate increases subcutaneous fat browning in male C57BL/6J mice fed a high-fat diet during adulthood. PLoS One. 2017 Nov 2;12 (11) :e0187507.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  PPARα; PPARγ

• CAS Number :

  [637-07-0]